STOCK TITAN

Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
earnings

TORONTO and HOUSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 13, 2021 at 8:30 AM ET to report its first quarter fiscal 2022 financial results and operational highlights.

To access the call, please dial (877) 407-9716 from the United States or (201) 493-6779 internationally, followed by the conference ID: 13721841. To access the live webcast, please go to the investors section of Medicenna’s website at https://ir.medicenna.com/news-and-events/events-and-presentations. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL-2 Superkine asset, MDNA11, is a next-generation IL-2 with potentially superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells unlike competing IL-2 programs. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to further enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.


Medicenna Therapeutics Corp

NASDAQ:MDNA

MDNA Rankings

MDNA Latest News

MDNA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing

About MDNA

medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca